Otitis MediaPhase 4NCT04600752
Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India
A Phase 4 study testing Augmentin (ES)-600 in people with Otitis Media and Infections, Respiratory Tract, run by GlaxoSmithKline at 13 sites in India.
Trial summary
Augmentin (ES)-600 is a high-dose amoxicillin/clavulanic acid 14:1 formulation that allows administration at 90/6.4 milligrams (mg)/kilograms (kg)/day in two divided doses. Most physicians in India use the standard Augmentin (amoxicillin:clavulanic acid 7:1) (45/6.4 mg/kg/day) formulation and double the dose to… Read more about this study
- Who is it for?
- Ages 6 months to 12 years
- Conditions the study is for
- Otitis Media, Infections, Respiratory Tract, Respiratory Tract Infections
- What is being tested?
- Augmentin (ES)-600
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 310 participants
- Where
- 13 sitesIndia
- Study dates
- 7 May 2022to 12 Nov 2022
- Phase
- Phase 4
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months to 12 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Participants aged: 6 months to 12 years; no gender restriction.
- Diagnosis of AOM on basis of otoscopic findings as defined below:
- Purulent otorrhea of less than 24 hours duration or
- Middle ear effusion
- Middle ear effusion is evidenced by at least two of the following:
- Decreased or absent tympanic mobility measured by pneumatic otoscopy,
Show all 14Show fewer
- Yellow or white discoloration of the tympanic membrane, or
- Opacification of the tympanic membrane plus
- At least one of the following indicators of acute inflammation:
- Ear pain within 24 hours, including unaccustomed tugging or rubbing of ear,
- Marked redness of the tympanic membrane, or
- Distinct fullness or bulging of the tympanic membrane.
- The participant and parent(s)/legal guardian(s) are willing and able to comply with the study protocol.
- In accordance with regional/local laws and regulations, the parent(s)/legal guardian(s) has given signed informed, dated consent; and the participant has given written assent, if applicable, to participate in the study.
Who cannot join
- Weight more than 40 kg.
- Spontaneous perforation of the tympanic membrane and drainage for longer than 24 hours.
- Tympanoplastic tube(s) in place, or has anatomic abnormalities associated with recurrent AOM, prolonged middle ear effusion, including cleft palate or repair, high-arched palate or Down's syndrome.
- A serious underlying disease as per clinician's judgment.
- Concomitant infection which would preclude evaluation of the response of his/her acute otitis media to the study intervention.
- Pre-existing renal insufficiency (plasma creatinine greater than [>]1.5 times upper limit of normal range for age).
Show all 16Show fewer
- Pre-existing liver disease(s) and/or hepatic dysfunction.
- Evidence of leukopenia and/or thrombocytopenia.
- History of previous hypersensitivity reaction to penicillins, cephalosporins or other beta-lactam antibiotics.
- History of Augmentin-associated cholestatic jaundice/hepatic dysfunction.
- History of phenylketonuria or a known hypersensitivity to aspartame.
- Received, within 48 hours of study entry, or is scheduled to receive during the study period, any medication which may alter bowel function.
- Currently receiving or has received more than one dose of systemic antibiotic therapy within one week prior to the initiation of the study. AOM treatment failures with Amoxicillin, erythromycin, sulfamethoxazole or Trimethoprim-Sulfamethoxazole are not subject to this criterion.
- Receipt of an investigational compound (non-Food and Drug Administration [FDA] and non- Drugs Controller General Of India [DCGI] approved) or device within the previous 30 days or five half-lives, whichever is longer, preceding the first dose of study intervention or during the study.
- Participants with symptoms suggestive of active Coronavirus Disease 2019 (COVID-19) infection (fever, cough, etc).
- Participants with known COVID-19 positive contacts within the past 14 days.
Trial locations and contacts
13 sites in 1 country.
13 sites in 1 country
India13 sites
GSK Investigational Site
Belgaun, 590010
GSK Investigational Site
Hyderabad, 500018
GSK Investigational Site
Jaipur, Rajasthan, 302016
GSK Investigational Site
Kanpur, 208002
GSK Investigational Site
Kolkata, 700017
GSK Investigational Site
Ludhiana, 141008
GSK Investigational Site
Madurai, 625107
GSK Investigational Site
Nagpur, 440009
GSK Investigational Site
New Delhi, 110002
GSK Investigational Site
Pune, 411043
GSK Investigational Site
Purne, 411030
GSK Investigational Site
Raipur, Chhattisgarh, 492099
GSK Investigational Site
Varanasi, Uttar Pradesh, 221001
About this study
Official title: A Multicenter, Open-label, Non-comparative Phase IV Clinical Study to Evaluate the Safety and Clinical Efficacy of Augmentin Extra Strength (ES)-600 in Children With Acute Otitis Media (AOM) in India
Augmentin (ES)-600 is a high-dose amoxicillin/clavulanic acid 14:1 formulation that allows administration at 90/6.4 milligrams (mg)/kilograms (kg)/day in two divided doses. Most physicians in India use the standard Augmentin (amoxicillin:clavulanic acid 7:1) (45/6.4 mg/kg/day) formulation and double the dose to achieve higher dose of amoxicillin/clavulanic acid at 90 mg/kg/day in pediatric acute otitis media (AOM) due to non-availability of Augmentin (ES)-600. Using the 7:1 formulation causes unnecessary exposure to higher proportionate dose of clavulanic acid (12.8 mg/kg/day) as a unit dose of 6.4 mg/kg/day of clavulanic acid is only required for efficacy against beta-lactamase producing AOM pathogens. Hence, there is an unmet need for availability of Augmentin (ES)-600 in India. This is an open label, single arm, multicenter, non-comparative study in participants aged 6 months to 12 years with AOM. It aims to assess the safety and clinical efficacy of Augmentin (ES)-600 administered in two divided doses, every 12 hours in pediatric population in India. AUGMENTIN is a registered trademark of the GlaxoSmithKline group of companies.
- Being tested
- Augmentin (ES)-600
- Keywords
- Acute otitis media, Augmentin Extra Strength, Amoxicillin-clavulanic acid, Pediatric, Beta-lactamase
- Medical subject headings
- Otitis Media, Respiratory Tract Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Augmentin (ES)-600Drug
Augmentin ES will be administered as reconstituted oral suspension containing Amoxicillin and Potassium Clavulanate 600 mg/42.9 mg per 5 milliliters.
| Study group | Role | What they receive |
|---|---|---|
| Participants receiving Augmentin (ES)-600 | Experimental | Eligible participants will receive Augmentin (ES)-600 at 90/6.4 mg/kg/day administered in two divided doses, every 12 hours with food for 10 days. Receives: Drug: Augmentin (ES)-600 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A treatment emergent AE event has its onset date on or after treatment start date and on or before treatment stop date + 1 day
Measured: Up to 28 days
Secondary outcomes (4)
Number of Participants With Early Clinical Response at On-therapy (OT) Visit
Early clinical response was categorized as treatment 'success' or treatment 'failure' at OT Visit (Day 3 to 5). Success was defined as 'clinical cure' that included sufficient resolution or improvement of the signs and symptoms such that no additional antibiotic therapy was indicated or 'improvement' that included improvement in at least 1 presenting signs/symptoms such that no additional antibiotic indicated. Failure is defined as 'Clinical Failure' that included as non-improvement or deterioration in any sign/symptoms after 2 or more days of therapy and additional antibiotic therapy is indicated or 'Unable to Determine' included a valid assessment of clinical outcome could not be made (eg, participant did not attend or consent to clinical examination or lost to follow-up). Participants who were not taking minimum 4 doses in two days were categorized as non evaluable.
Measured: On-therapy (OT) visit (Day 3 to 5)
Number of Participants With Primary Clinical Response at End of Therapy (EOT)
Primary clinical response at the end-of-therapy visit was categorized as treatment 'success' or treatment 'failure'. Success was defined as 'Clinical Cure' that included sufficient resolution or improvement of the signs and symptoms that no additional antibiotic therapy was indicated or 'Improvement' that included improvement, but incomplete resolution of presenting signs/symptoms and no additional antibiotic indicated. Failure is defined as 'Clinical Failure' that included non-improvement or deterioration in any sign/symptoms after 2 or more days of therapy and additional antibiotic therapy indicated, or 'Unable to determine' defined as a valid assessment of clinical outcome could not be made (e.g., participant did not attend or consent to clinical examination or lost to follow-up). Non-Evaluable is defined as participants who had less than (<) 80% compliance
Measured: End of therapy visit (Day 12 to 14)
Number of Participants With Secondary Clinical Response at Follow-up (FU)
Secondary clinical response at follow-up was categorized as treatment 'success' or treatment 'failure'. Success was defined as 'Persistent clinical cure' that included sufficient resolution of signs/symptoms for those participants who were clinically cured or improved at the end of therapy and no additional antibiotic indicated. Failure was defined as 'Clinical recurrence' that included reappearance of signs/symptoms for those participants who were clinically cured or improved at the end of therapy and additional antibiotic therapy was indicated, or 'Unable to determine' that included valid assessment of clinical outcome could not be made (e.g., participant did not attend end of therapy visit, or extenuating circumstances or lost to follow-up). Participant with missing responses were categorized as 'Missing'.
Measured: Follow up visit (Day 22 to 28)
Number of Participants With Protocol-defined Diarrhea (PDD) (Due to Study Medication)
Protocol-defined diarrhea was defined as a) 3 or more watery stools in one day or b) 4 or more loose/watery stools in one day or c) 2 watery stools per day for two consecutive days or d) 3 loose/watery stools per day for two consecutive days.
Measured: From OT visit (Day 3 to 5) to FU visit (Day 22-28)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2020
- Study start7 May 2022
- Primary completion12 Nov 2022
- Study completion12 Nov 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Otitis MediaStudies of the same condition, open and under way.
- More trials run by GlaxoSmithKlineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is a single arm, multicenter, non-comparative study.
- Masking
- None (open label)
- Enrolment
- 310 participants (actual)
Sponsor and investigators
- Lead sponsor
- GlaxoSmithKline
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- IQVIA Pty Ltd
- Responsible party
- Sponsor
- Investigators
- GSK Clinical Trials, Study director, GlaxoSmithKline
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04600752
- Sponsor's protocol ID
- 213514
- Status last verified
- May 2024
- First submitted
- 19 Oct 2020
- Last updated
- 10 Jun 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD for this study will be made available via the Clinical Study Data Request site.